Literature DB >> 15605305

Effects of weight loss surgeries on liver disease.

George L Blackburn1, Edward C Mun.   

Abstract

Obesity is the single most significant risk factor for the development of nonalcoholic fatty liver disease (NAFLD) in children and adults. NALFD is estimated to occur in 30 to 100% of obese adults, and in approximately 53% of obese children. The majority of obese patients have ultrasonographic evidence of fatty liver; 30% have histologically documented nonalcoholic steatohepatitis (NASH). Up to 25% of patients with NASH may progress to cirrhosis. In the United States, an estimated 65% of adults are overweight and 31% are obese. Between 2001 and 2002, the number of people with severe obesity, who are more than 100 pounds overweight, rose to nearly 11 million. Since 1970, levels of childhood and teen overweight have climbed to approximately 16% in those aged 6 to 19 years. Recent findings indicate that key features of NAFLD and NASH improve or resolve dramatically with weight loss. This article discusses weight loss surgeries and their effects on liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605305     DOI: 10.1055/s-2004-860866

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  15 in total

1.  Nonalcoholic fatty liver disease treated by gastroplasty.

Authors:  K Jaskiewicz; S Raczynska; R Rzepko; Z Sledziński
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Obese Adolescents Report Better Health-Related Quality of Life than Obese Young Adults.

Authors:  John B Dixon; Toni L Rice; Elisabeth A Lambert; Gavin W Lambert
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

Review 3.  Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery.

Authors:  Andrea Lazzati; Antonio Iannelli; Anne-Sophie Schneck; Anaïs Charles Nelson; Sandrine Katsahian; Jean Gugenheim; Daniel Azoulay
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

4.  Recent Advances in the Treatment of NASH.

Authors:  Steven H Caldwell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

5.  Medical Care of the Patient With Compensated Cirrhosis.

Authors:  Jorge L Herrera; Reynaldo Rodríguez
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-02

6.  Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  Samer G Mattar; Laura M Velcu; Mordechai Rabinovitz; A J Demetris; A M Krasinskas; Emma Barinas-Mitchell; George M Eid; Ramesh Ramanathan; Debra S Taylor; Philip R Schauer
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

7.  Nonalcoholic fatty liver disease during valproate therapy.

Authors:  Alberto Verrotti; Giovanna Di Marco; Rosanna la Torre; Piernicola Pelliccia; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2009-01-30       Impact factor: 3.183

8.  The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.

Authors:  Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

9.  Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients.

Authors:  Víctor Vargas; Helena Allende; Albert Lecube; Maria Teresa Salcedo; Juan A Baena-Fustegueras; José M Fort; Joaquín Rivero; Roser Ferrer; Roberto Catalán; Eva Pardina; Santiago Ramón Y Cajal; Jaime Guardia; Julia Peinado-Onsurbe
Journal:  World J Hepatol       Date:  2012-12-27

Review 10.  Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Kamran Qureshi; Gary A Abrams
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.